ADAR1 Capital Management, LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001940272
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2025 · 201 positions · Total reported value $980.12M · Top-10 concentration 52.1% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 47.5% · 33 new · 62 cut · 48 exited
Active Share (vs S&P 500): 98.9% · vs QQQ: 99.4% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -7.0% · vs SPY -9.1% · Prev Value $1.81B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -3.7% · vs SPY -5.9% · Latest Value $1.82B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q3 2025 13F filing, ADAR1 Capital Management, LLC disclosed 201 equity positions with a combined reported value of $980.12M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 52.1% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2025 were ABVX ($114.69M), KROS ($85.26M), PTGX ($65.71M). By sector, the heaviest allocations are Health Care 78.6%, Financials 1.2%. Versus the prior quarter, allocation shifted toward Health Care (+4.3pp) and away from Other (-4.2pp).
Versus the prior quarter, ADAR1 Capital Management, LLC opened 33 new positions, trimmed 62 and fully exited 48, a turnover rate of 47.5% of positions. The portfolio's overlap with the prior quarter was 61% of names.
The largest new positions opened in Q3 2025 were IVVD ($8.11M), MTSR ($7.98M), EQ ($7.95M).
Of the 48 positions fully exited versus the prior quarter, the largest were SAGE ($6.58M), VERV ($5.27M), HLXB ($4.70M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2025)
- IVVD INVIVYD INC · $8.11M
- MTSR METSERA INC · $7.98M
- EQ EQUILLIUM INC · $7.95M
- QURE UNIQURE NV · $7.78M
- BBOT BRIDGEBIO ONCOLOGY THERAPEUT · $5.80M
- ATAI Ataibeckley Inc CVR · $4.83M
- UTHR UNITED THERAPEUTICS CORP DEL · $4.70M
- XBI SPDR SERIES TRUST · $4.01M
Fully Exited (vs previous quarter)
- SAGE SAGE THERAPEUTICS INC · prev qtr: $6.58M
- VERV VERVE THERAPEUTICS INC · prev qtr: $5.27M
- HLXB HELIX ACQUISITION CORP II · prev qtr: $4.70M
- SHY ISHARES TR · prev qtr: $4.42M
- ARDX ARDELYX INC · prev qtr: $3.59M
- THRD THIRD HARMONIC BIO INC · prev qtr: $3.38M
- ALEC ALECTOR INC · prev qtr: $2.41M
- CRMD CORMEDIX INC · prev qtr: $2.16M
Insider Transactions (Form 4)
Latest ADAR1 Capital Management, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-11-11 | Buy | NextCure, Inc. | 12,333 | $5.10 | SEC filing |
| 2026-11-06 | Buy | NextCure, Inc. | 3,662 | $5.10 | SEC filing |
| 2026-11-05 | Buy | InMed Pharmaceuticals Inc. | 2,640 | $13.10 | SEC filing |
| 2026-11-05 | Buy | NextCure, Inc. | 1,024 | $5.10 | SEC filing |
| 2026-10-27 | Buy | NextCure, Inc. | 3,553 | $5.10 | SEC filing |
| 2026-10-26 | Buy | NextCure, Inc. | 1,672 | $5.03 | SEC filing |
| 2026-10-23 | Buy | InMed Pharmaceuticals Inc. | 4 | $1.32 | SEC filing |
| 2026-10-23 | Buy | NextCure, Inc. | 5,626 | $4.83 | SEC filing |
Fund Profile
ADAR1 Capital Management, LLC is an SEC-registered 13F filer based in Austin, TX, United States. As of Q2 2026 it reported 268 US equity positions with a combined value of $1.81B. HoldingsHub carries 11 quarters of its filings (Q4 2023–Q2 2026).
Firm Snapshot
- Headquarters: AUSTIN, TX, United States
- SEC registration: 801-130082 (status: Approved), registered 2024-04-25
- Regulatory AUM (Form ADV): $1.68B as of 2026-03-31
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 2 private funds, of which 2 hedge funds
Portfolio Structure
- 268 positions · $1.81B reported value (Q2 2026)
- Top 10 holdings = 34.2% of reported value
- Largest position: PTGX (PROTAGONIST THERAPEUTICS INC) at 6.5%
- Average position size: $6.74M
Sector Tilt
- Health Care 86.5%
- Financials 2.6%
- Industrials 0.4%
- (classified holdings cover 90% of value)
Quarterly Activity
- Q2 2026: 42 new, 99 added, 60 reduced, 69 exited
- 67 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
1.35M | $114.69M | 11.70% | Reduce | |
| 2 |
|
5.39M | $85.26M | 8.70% | Hold | |
| 3 |
|
989.18K | $65.71M | 6.70% | Add | |
| 4 |
|
3.35M | $50.65M | 5.17% | Add | |
| 5 |
|
337.12K | $38.39M | 3.92% | Hold | |
| 6 |
|
2.24M | $36.14M | 3.69% | Add | |
| 7 |
|
2.11M | $31.06M | 3.17% | Add | |
| 8 |
|
45.50K | $30.31M | 3.09% | Add | |
| 9 |
|
868.78K | $29.44M | 3.00% | Add | |
| 10 |
|
518.92K | $28.52M | 2.91% | Reduce | |
| 11 |
|
1.18M | $22.13M | 2.26% | Add | |
| 12 |
|
1.47M | $14.34M | 1.46% | Reduce | |
| 13 |
|
2.90M | $13.18M | 1.34% | Add | |
| 14 |
|
507.77K | $13.10M | 1.34% | Reduce | |
| 15 |
|
4.05M | $12.90M | 1.32% | Add | |
| 16 |
|
135.59K | $12.44M | 1.27% | Hold | |
| 17 |
|
866.20K | $11.77M | 1.20% | Reduce | |
| 18 |
|
1.88M | $11.05M | 1.13% | Reduce | |
| 19 |
|
130.00K | $10.62M | 1.08% | Add | |
| 20 |
|
248.37K | $10.34M | 1.05% | Add | |
| 21 |
|
1.53M | $10.17M | 1.04% | Add | |
| 22 |
|
248.92K | $10.03M | 1.02% | Reduce | |
| 23 |
|
2.84M | $9.27M | 0.95% | Reduce | |
| 24 |
|
15.70K | $8.83M | 0.90% | Add | |
| 25 |
|
133.82K | $8.75M | 0.89% | Reduce | |
| 26 |
|
351.03K | $8.58M | 0.88% | Add | |
| 27 |
|
5.25M | $8.50M | 0.87% | Add | |
| 28 |
|
7.37M | $8.11M | 0.83% | New | |
| 29 |
|
152.52K | $7.98M | 0.81% | New | |
| 30 |
|
5.56M | $7.95M | 0.81% | New | |
| 31 |
|
750.00K | $7.92M | 0.81% | Hold | |
| 32 |
|
133.32K | $7.78M | 0.79% | New | |
| 33 |
|
213.06K | $7.67M | 0.78% | Add | |
| 34 |
|
815.98K | $7.67M | 0.78% | Reduce | |
| 35 |
|
189.10K | $7.59M | 0.78% | Reduce | |
| 36 |
|
36.34K | $7.23M | 0.74% | Add | |
| 37 |
|
1.99M | $7.10M | 0.72% | Reduce | |
| 38 |
|
349.81K | $6.74M | 0.69% | Add | |
| 39 |
|
139.14K | $6.50M | 0.66% | Add | |
| 40 |
|
501.23K | $5.80M | 0.59% | New | |
| 41 |
|
51.45K | $5.49M | 0.56% | Add | |
| 42 |
|
516.48K | $5.48M | 0.56% | Hold | |
| 43 |
|
267.82K | $5.41M | 0.55% | Reduce | |
| 44 |
|
49.57K | $5.01M | 0.51% | Add | |
| 45 |
|
913.24K | $4.83M | 0.49% | New | |
| 46 |
|
11.20K | $4.70M | 0.48% | New | |
| 47 |
|
175.92K | $4.62M | 0.47% | Add | |
| 48 |
|
405.09K | $4.26M | 0.43% | Reduce | |
| 49 |
|
72.01K | $4.10M | 0.42% | Add | |
| 50 |
|
40.00K | $4.01M | 0.41% | New | |
FAQ
What did ADAR1 Capital Management, LLC buy in 2025-Q3?
In its 2025-Q3 13F filing, ADAR1 Capital Management, LLC reported 201 equity positions worth $980.12M in aggregate; its largest disclosed positions were ABVX ($114.69M), KROS ($85.26M), PTGX ($65.71M).
How large is ADAR1 Capital Management, LLC's portfolio?
ADAR1 Capital Management, LLC reported $980.12M of long equity holdings across 201 positions as of 2025-Q3. Top-10 holdings account for 52.1% of reported value.
What is ADAR1 Capital Management, LLC's investment style?
HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.